<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134834</url>
  </required_header>
  <id_info>
    <org_study_id>OP0595-1</org_study_id>
    <nct_id>NCT02134834</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of OP0595 Administered Intravenously in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meiji Seika Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meiji Seika Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety, tolerability and pharmacokinetic&#xD;
      profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at&#xD;
      single escalating doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety from baseline through the end of the study</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Number of patients with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of OP0595 and its metabolites</measure>
    <time_frame>Day 1 to Day 2</time_frame>
    <description>Cmax, tmax, AUC0-last, AUC0-inf, Kel, T1/2, CLtot, Vdss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PK parameters of OP0595 and its metabolites</measure>
    <time_frame>Day 1 to Day 2</time_frame>
    <description>Ae, Ae0-t, Ae0-t/Dose, CLr</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Ascending single dose of OP0595</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OP0595</intervention_name>
    <description>Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation</description>
    <arm_group_label>Ascending single dose of OP0595</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian males aged between 18 and 45 years (inclusive) at Screening&#xD;
&#xD;
          -  A Body Mass Index (BMI) between 18.0 and 30.0 kg/mÂ² (inclusive) at Screening&#xD;
&#xD;
          -  Good general health as determined by the Investigator based on medical history,&#xD;
             physical examination, vital signs, 12-lead ECG and clinical laboratory tests&#xD;
&#xD;
          -  Negative urine test for drugs of abuse and breath test for alcohol both at Screening&#xD;
             and Day -1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any investigational agent or drug within four months before Screening&#xD;
&#xD;
          -  A history or current evidence of allergic symptoms such as bronchial asthma,&#xD;
             drug-induced rash or urticaria&#xD;
&#xD;
          -  Hypersensitivity and/or allergy to drugs&#xD;
&#xD;
          -  Concurrent or history of clinically significant cardiovascular, hepatic, renal,&#xD;
             endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or hematological&#xD;
             disorders&#xD;
&#xD;
          -  A history of chronic or recurrent infections or current active infection&#xD;
&#xD;
          -  A recent history of surgery within three months prior to Screening, determined by the&#xD;
             Investigator to be clinically relevant&#xD;
&#xD;
          -  A history or presence of malignancy&#xD;
&#xD;
          -  Donation of blood (or loss of blood) greater than 400 ml within three months before&#xD;
             Screening&#xD;
&#xD;
          -  A history of smoking at any time within one year before Screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuharu Egawa</last_name>
    <role>Study Chair</role>
    <affiliation>Meiji Seika Pharma Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Perth,</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

